問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Study Site

Study Site



Taipei Medical University Hospital

  • 0

    Total Beds

  • 0

    Total Doctors

  • 110Taipei CitySin Yi

Recruiting Trial

211Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

List

424Cases

2010-07-07 - 2012-07-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2007-09-01 - 2008-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2017-01-01 - 2020-02-29

Phase III

A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 Compared with Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Patients with Influenza at High Risk of Influenza Complications

  • Condition/Disease

    Influenza

  • Test Drug

    S-033188

Participate Sites
11Sites

Terminated11Sites

2018-06-29 - 2022-06-30

Phase II

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of BMS-986165 in Subjects With Systemic Lupus Erythematosus

  • Condition/Disease

    Systemic Lupus Erythematosus

  • Test Drug

    BMS-986165

Participate Sites
8Sites

Recruiting8Sites

張棋楨
Taipei Medical University Hospital

2018-09-01 - 2019-02-28

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Not yet recruiting1Sites

2018-07-01 - 2020-12-31

Phase II

Randomized, controlled, open label, clinical trial for - adagloxad simolenin/OBI-821 in combination with TACE therapy in hepatocellular carcinoma patients with GALNT14-rs9679162-non-TT genotype

  • Condition/Disease

    Hepatocellular Carcinoma

  • Test Drug

    Adagloxad simolenin (OBI-822)/OBI-821

Participate Sites
5Sites

Terminated4Sites

2016-01-01 - 2016-12-31

Others

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

劉明哲
Taipei Medical University Hospital

2017-09-30 - 2022-09-30

Phase I

A Phase 1 Study of HLX06, a Fully Human Monoclonal Antibody Targeting Human Vascular Endothelial Growth Factor Receptor-2 in Patients with Advanced Solid Tumors Refractory to Standard Therapy

  • Condition/Disease

    Patients with Advanced Solid Tumors Refractory to Standard Therapy

  • Test Drug

    HLX06

Participate Sites
3Sites

Terminated3Sites

趙祖怡
Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Hematology & Oncology

2020-01-24 - 2021-12-31

Phase II

A Phase 2a Proof-of-Concept Study of R-107 for the Treatment of Refractory Major Depressive Disorder

  • Condition/Disease

    Refractory Major Depressive Disorder

  • Test Drug

    R-107

Participate Sites
3Sites

Recruiting3Sites

2018-09-01 - 2022-05-25

Phase III

A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients with Moderately to Severely Active Ulcerative Colitis LUCENT 2

  • Condition/Disease

    Moderately to Severely Active Ulcerative Colitis

  • Test Drug

    Mirikizumab

Participate Sites
12Sites

Recruiting10Sites

Terminated1Sites

周仁偉
China Medical University Hospital-Taipei

未分科

1 34 35 36 37 38 43
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB